Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug candidate targets Hard-to-Treat lung condition

NCT ID NCT06137742

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This early-stage study by Pfizer tests a new drug called PF-07868489. First, it will be given to healthy volunteers to check safety and how the body processes it. Then, people with pulmonary arterial hypertension (PAH) will receive repeated doses over 24 weeks to see if it helps their condition. The main goal is safety, but researchers will also measure effects on blood pressure in the lungs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PF-07868489
What this could lead to
If it works, this could point toward a new treatment option for pulmonary arterial hypertension, a serious lung condition.
What could go wrong
This is a very early Phase 1/2 trial with only 97 participants. The drug may not prove safe or effective, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

97 people

The number who actually took part.

Started

Nov 2023

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria Part A: * overtly healthy * Body mass index (BMI) of 16 to 32 kg/m2; and a total body weight \>50 kg. Key Exclusion Criteria Part A: * clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, infections or allergic disease. * smoking more than 10 cigarettes (or equivalent) per day or smoking history ≥10 pack-years. Key Inclusion Criteria Part B: * diagnosis of pulmonary arterial hypertension (PAH) * stable dose of standard of care PAH vasodilators * BMI 16 to 40 kg/m2; and a total body weight \>45 kg. * 6MWD ≥ 150 and ≤ 450. * Pre-randomization RHC documenting a minimum of PVR ≥ 400 dyn ∙sec/cm5. Key Exclusion Criteria Part B: * Any medical or psychiatric condition or laboratory abnormality. * Stopped receiving pulmonary hypertension chronic general supportive therapy 90 days prior to Day 1. * Pulmonary capillary wedge pressure \> 15 mmHg on right heart catheterization (RHC) conducted during Screening. * History of severe allergic or anaphylactic reaction or hypersensitivity to recombinant proteins or excipients in investigational product. * Major surgery within 8 weeks prior to randomization. * Participants who smoke more than 10 cigarettes (or equivalent) per day or has a smoking history ≥10 pack-years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary arterial hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary arterial hypertension

Contacts and locations

Locations

  • Anaheim Clinical Trials, LLC

    Anaheim, California, 92801, United States

  • CHRU de Brest

    Brest, Finistère, 29200, France

  • CHRU de Brest

    Brest, Finistère, 29609, France

  • Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord

    Saint Priest En Jarez, Pays de la Loire Region, 42270, France

  • Eastowne 100 Medical Office Building

    Chapel Hill, North Carolina, 27514, United States

  • Eastowne Medical Office Building - Clinical Research Unit

    Chapel Hill, North Carolina, 27514, United States

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, 27100, Italy

  • Gachon University Gil Medical Center

    Namdong-gu, Incheon-gwangyeoksi [incheon], 21565, South Korea

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, 510080, China

  • Hammersmith Hospital

    London, London, CITY of, W12 0HS, United Kingdom

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario La Paz

    Madrid, Madrid, Comunidad de, 28046, Spain

  • Icahn school of medicine at Mount Sinai

    New York, New York, 10029, United States

  • Investigational Drug Services Pharmacy

    Morrisville, North Carolina, 27560, United States

  • Kobe University Hospital

    Kobe, Hyōgo, 650-0017, Japan

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

  • Medical University of South Carolina - Nexus

    Charleston, South Carolina, 29425, United States

  • Medical University of South Carolina - Radiology

    Charleston, South Carolina, 29425, United States

  • Mount Sinai Hospital

    New York, New York, 10029, United States

  • National Hospital Organization Okayama Medical Center

    Okayama, 701-1154, Japan

  • Pulmonary Hypertension Research Queensland Pty Ltd

    Auchenflower, Queensland, 4066, Australia

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, 2050, Australia

  • Samsung Medical Center

    Seoul, Seoul-teukbyeolsi [seoul], 06351, South Korea

  • Seoul National University Hospital

    Seoul, Seoul-teukbyeolsi [seoul], 03080, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, Seoul-teukbyeolsi [seoul], 03722, South Korea

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, 200433, China

  • St. Marianna University Hospital

    Kawasaki, Kanagawa, 216-8511, Japan

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, 410011, China

  • Thoraxklinik-Heidelberg gGmbH

    Heidelberg, Baden-Wurttemberg, 69126, Germany

  • Tohoku University Hospital

    Sendai, Miyagi, 980-8574, Japan

  • UCI Health - Costa Mesa

    Costa Mesa, California, 92627, United States

  • UCI Health Center for Innovative Health Therapies (CIHT)

    Orange, California, 92868, United States

  • UCSF Health St. Mary's Hospital

    San Francisco, California, 94117, United States

  • UCSF Helen Diller Medical Center at Parnassus Heights

    San Francisco, California, 94143, United States

  • UKGM Gießen/Marburg

    Giessen, Hesse, 35392, Germany

  • UNC Health - Eastowne Medical Office

    Chapel Hill, North Carolina, 27514, United States

  • UNC Hospitals

    Chapel Hill, North Carolina, 27514, United States

  • UZ Leuven

    Leuven, Vlaams-brabant, 3000, Belgium

  • Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden

    Dresden, Saxony, 01307, Germany

  • University of California, Irvine Medical Center

    Orange, California, 92868, United States

  • Universitätsklinikum Regensburg

    Regensburg, Bavaria, 93053, Germany

  • Universitätsmedizin Greifswald

    Greifswald, Mecklenburg-Vorpommern, 17475, Germany

  • Université Libre de Bruxelles - Hôpital Erasme

    Brussels, Bruxelles-capitale, Région de, 1070, Belgium

  • Vseobecna fakultni nemocnice v Praze

    Prague, 12808, Czechia

  • Wesley Research Institute

    Auchenflower, Queensland, 4066, Australia

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, 210009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.